nach oben

Heart Failure Reviews

Erschienen in:

12.02.2018

Devices and interventions for the prevention of adverse outcomes of tachycardia on heart failure

verfasst von: Jasneet Devgun, Yash B. Jobanputra, Michael Arustamyan, Robert Chait, Waqas Ghumman

Erschienen in: Heart Failure Reviews | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Heart failure (HF) is the leading cause of hospitalization in the USA. Despite advances in pharmacologic management, the incidence of HF is on the rise and survivability is persistently reduced. Sympathetic overdrive is implicated in the pathophysiology of HF, particularly HF with reduced ejection fraction (HFrEF). Tachycardia can be particularly deleterious and thus has spurred significant investigation to mitigate its effects. Various modalities including vagus nerve stimulation, baroreceptor activation therapy, spinal cord stimulation, renal sympathetic nerve denervation, left cardiac sympathetic denervation, and carotid body removal will be discussed. However, the effects of these modalities on tachycardia and its outcomes in HFrEF have not been well-studied. Further studies to characterize this are necessary in the future.

Lachowska K, Gruchała M, Narkiewicz K, Hering D (2016) Sympathetic activation in chronic heart failure: potential benefits of interventional therapies. Curr Hypertens Rep 18(7):51. https://doi.org/10.1007/s11906-016-0660-7 CrossRefPubMed

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL (2013) 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128(16):1810–1852. https://doi.org/10.1161/CIR.0b013e31829e8807 CrossRefPubMed

Gold MR, Van Veldhuisen DJ, Hauptman PJ, Borggrefe M, Kubo SH, Lieberman RA, Milasinovic G, Berman BJ, Djordjevic S, Neelagaru S, Schwartz PJ, Starling RC, Mann DL (2016) Vagus nerve stimulation for the treatment of heart failure: the INOVATE-HF Trial. J Am Coll Cardiol 68(2):149–158. https://doi.org/10.1016/j.jacc.2016.03.525 CrossRefPubMed

Swedberg K, Komajda M, Böhm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (London, England) 376:875–885. https://doi.org/10.1016/S0140-6736(10)61198-1 CrossRef

Böhm M, Swedberg K, Komajda M et al (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet (London, England) 376:886–894. https://doi.org/10.1016/S0140-6736(10)61259-7 CrossRef

Zannad F, McMurray JJV, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21. https://doi.org/10.1056/NEJMoa1009492 CrossRefPubMed

McMurray JJV, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077 CrossRefPubMed

Floras JS (2009) Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 54(5):375–385. https://doi.org/10.1016/j.jacc.2009.03.061 CrossRefPubMed

Miller RJH, Howlett JG (2017) Does heart rate really matter to patients with heart failure? Curr Opin Cardiol 32:209–216. https://doi.org/10.1097/HCO.0000000000000368 PubMedCrossRef

10.

O’Neal WT, Sandesara PB, Samman-Tahhan A, Kelli HM, Hammadah M, Soliman EZ (2017) Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. Eur J Prev Cardiol 24(11):1212–1219. https://doi.org/10.1177/2047487317708676 CrossRefPubMedPubMedCentral

11.

Castagno D, Skali H, Takeuchi M et al (2012) Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (candesartan in heart failure: assessment of reduction in mortality and morbidity) program. J Am Coll Cardiol 59(20):1785–1795. https://doi.org/10.1016/j.jacc.2011.12.044 CrossRefPubMed

12.

Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikowski P, Voors AA, Dominjon F, Henon-Goburdhun C, Pannaux M, Böhm M, on behalf of the prEserveD left ventricular ejectIon fraction chronic heart Failure with ivabradine studY (EDIFY) Investigators (2017) Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail 19(11):1495–1503. https://doi.org/10.1002/ejhf.876 CrossRefPubMed

13.

Schwartz PJ, De Ferrari GM, Sanzo A, Landolina M, Rordorf R, Raineri C, Campana C, Revera M, Ajmone-Marsan N, Tavazzi L, Odero A (2008) Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail 10(9):884–891. https://doi.org/10.1016/j.ejheart.2008.07.016 CrossRefPubMed

14.

Premchand RK, Sharma K, Mittal S et al (2014) Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial. J Card Fail 20(11):808–816. https://doi.org/10.1016/j.cardfail.2014.08.009 CrossRefPubMed

15.

Zannad F, De Ferrari GM, Tuinenburg AE, Wright D, Brugada J, Butter C, Klein H, Stolen C, Meyer S, Stein KM, Ramuzat A, Schubert B, Daum D, Neuzil P, Botman C, Castel MA, D'Onofrio A, Solomon SD, Wold N, Ruble SB (2015) Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J 36(7):425–433. https://doi.org/10.1093/eurheartj/ehu345 CrossRefPubMed

16.

Schwartz PJ, La Rovere MT, De Ferrari GM, Mann DL (2015) Autonomic modulation for the management of patients with chronic heart failure. Circ Heart Fail 8(3):619–628. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001964 CrossRefPubMed

17.

Li M, Zheng C, Sato T et al (2004) Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109(1):120–124. https://doi.org/10.1161/01.CIR.0000105721.71640.DA CrossRefPubMed

18.

Zhang Y, Popovic ZB, Bibevski S, Fakhry I, Sica DA, van Wagoner DR, Mazgalev TN (2009) Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ Heart Fail 2(6):692–699. https://doi.org/10.1161/CIRCHEARTFAILURE.109.873968 CrossRefPubMed

19.

Vanoli E, De Ferrari GM, Stramba-Badiale M, Hull SS, Foreman RD, Schwartz PJ (1991) Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res 68(5):1471–1481. https://doi.org/10.1161/01.RES.68.5.1471 CrossRefPubMed

20.

Buckley U, Shivkumar K, Ardell JL (2015) Autonomic regulation therapy in heart failure. Curr Heart Fail Rep 12(4):284–293. https://doi.org/10.1007/s11897-015-0263-7 CrossRefPubMedPubMedCentral

21.

Halbach M, Fritz T, Madershahian N et al (2016) Baroreflex activation therapy in heart failure with reduced ejection fraction: available data and future perspective. Curr Heart Fail Rep 13(2):71–76. https://doi.org/10.1007/s11897-016-0286-8 CrossRefPubMed

22.

Kishi T (2016) Deep and future insights into neuromodulation therapies for heart failure. J Cardiol 68(5):368–372. https://doi.org/10.1016/j.jjcc.2016.05.010 CrossRefPubMed

23.

Sabbah HN, Gupta RC, Imai M, Irwin ED, Rastogi S, Rossing MA, Kieval RS (2011) Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure. Circ Heart Fail 4(1):65–70. https://doi.org/10.1161/CIRCHEARTFAILURE.110.955013 CrossRefPubMed

24.

Zucker IH, Hackley JF, Cornish KG et al (2007) Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertens (Dallas, Tex 1979) 50:904–910. https://doi.org/10.1161/HYPERTENSIONAHA.107.095216 CrossRef

25.

Georgakopoulos D, Wagner D, Cates AW et al (2009) Effects of electrical stimulation of the carotid sinus baroreflex using the Rheos device on ventricular-vascular coupling and myocardial efficiency assessed by pressure-volume relations in non-vagotomized anesthetized dogs. Conf Proc Annu Int Conf IEEE Eng Med Biol Soc IEEE Eng Med Biol Soc Annu Conf 2009:2025–2029. https://doi.org/10.1109/IEMBS.2009.5334421 CrossRef

26.

Gronda E, Seravalle G, Brambilla G et al (2014) Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail 16(9):977–983. https://doi.org/10.1002/ejhf.138 CrossRefPubMedPubMedCentral

27.

Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Müller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC (2015) Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail 3(6):487–496. https://doi.org/10.1016/j.jchf.2015.02.006 CrossRefPubMed

28.

Shen MJ, Zipes DP (2015) Interventional and device-based autonomic modulation in heart failure. Heart Fail Clin 11(2):337–348. https://doi.org/10.1016/j.hfc.2014.12.010 CrossRefPubMed

29.

Tse H-F, Turner S, Sanders P, Okuyama Y, Fujiu K, Cheung CW, Russo M, Green MDS, Yiu KH, Chen P, Shuto C, Lau EOY, Siu CW (2015) Thoracic spinal cord stimulation for heart failure as a restorative treatment (SCS HEART study): first-in-man experience. Hear Rhythm 12(3):588–595. https://doi.org/10.1016/j.hrthm.2014.12.014 CrossRef

30.

Zipes DP, Neuzil P, Theres H et al (2016) Determining the feasibility of spinal cord Neuromodulation for the treatment of chronic systolic heart failure: the DEFEAT-HF study. JACC Heart Fail 4(2):129–136. https://doi.org/10.1016/j.jchf.2015.10.006 CrossRefPubMed

31.

Upadhyay GA, Singh JP (2016) Spinal cord stimulation for heart failure in the DEFEAT-HF study: lost battle or lasting opportunities? JACC Heart Fail 4(2):137–139. https://doi.org/10.1016/j.jchf.2015.11.007 CrossRefPubMed

32.

Schiller AM, Haack KKV, Pellegrino PR, Curry PL, Zucker IH (2013) Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure. Am J Physiol Regul Integr Comp Physiol 305(8):R886–R892. https://doi.org/10.1152/ajpregu.00269.2013 CrossRefPubMedPubMedCentral

33.

Schiller AM, Pellegrino PR, Zucker IH (2015) The renal nerves in chronic heart failure: efferent and afferent mechanisms. Front Physiol 6:224. https://doi.org/10.3389/fphys.2015.00224 CrossRefPubMedPubMedCentral

34.

Linz D, Wirth K, Ukena C, Mahfoud F, Pöss J, Linz B, Böhm M, Neuberger HR (2013) Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs. Hear Rhythm 10(10):1525–1530. https://doi.org/10.1016/j.hrthm.2013.07.015 CrossRef

35.

Bealer SL (2002) Systemic angiotensin II alters intrinsic heart rate through central mechanisms. Brain Res Bull 58(1):61–65. https://doi.org/10.1016/S0361-9230(02)00756-6 CrossRefPubMed

36.

Davies JE, Manisty CH, Petraco R, Barron AJ, Unsworth B, Mayet J, Hamady M, Hughes AD, Sever PS, Sobotka PA, Francis DP (2013) First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol 162(3):189–192. https://doi.org/10.1016/j.ijcard.2012.09.019 CrossRefPubMed

37.

Hopper I, Gronda E, Hoppe UC et al (2017) Sympathetic response and outcomes following renal denervation in patients with chronic heart failure: 12-month outcomes from the symplicity HF feasibility study. J Card Fail 23(9):702–707. https://doi.org/10.1016/j.cardfail.2017.06.004 CrossRefPubMed

38.

Pekarskiy SE, Baev AE, Mordovin VF, Semke GV, Ripp TM, Falkovskaya AU, Lichikaki VA, Sitkova ES, Zubanova IV, Popov SV (2017) Denervation of the distal renal arterial branches vs. conventional main renal artery treatment: a randomized controlled trial for treatment of resistant hypertension. J Hypertens 35(2):369–375. https://doi.org/10.1097/HJH.0000000000001160 CrossRefPubMed

39.

Fukuta H, Goto T, Wakami K, Ohte N (2017) Effects of catheter-based renal denervation on heart failure with reduced ejection fraction: a systematic review and meta-analysis. Heart Fail Rev 22(6):657–664. https://doi.org/10.1007/s10741-017-9629-0 CrossRefPubMed

40.

Schwartz PJ, De Ferrari GM, Pugliese L (2017) Cardiac sympathetic denervation 100years later: Jonnesco would have never believed it. Int J Cardiol 237:25–28. https://doi.org/10.1016/j.ijcard.2017.03.020 CrossRefPubMed

41.

Vaseghi M, Barwad P, Malavassi Corrales FJ et al (2017) Cardiac sympathetic denervation for refractory ventricular arrhythmias. J Am Coll Cardiol 69(25):3070–3080. https://doi.org/10.1016/j.jacc.2017.04.035 CrossRefPubMed

42.

Schwartz PJ (2014) Cardiac sympathetic denervation to prevent life-threatening arrhythmias. Nat Rev Cardiol 11(6):346–353. https://doi.org/10.1038/nrcardio.2014.19 CrossRefPubMed

43.

Guo W, Liu F, Fu L, Qu R, Wang G, Zhang C (2012) Effects of high thoracic epidural sympathetic blockade for the treatment of severe chronic heart failure due to dilated cardiomyopathy. Acta Cardiol 67(5):533–539. https://doi.org/10.2143/AC.67.5.2174127 CrossRefPubMed

44.

Chin A, Ntsekhe M, Viljoen C, Rossouw J, Pennel T, Schwartz PJ (2017) Rationale and design of a prospective study to assess the effect of left cardiac sympathetic denervation in chronic heart failure. Int J Cardiol 248:227–231. https://doi.org/10.1016/j.ijcard.2017.08.012 CrossRefPubMed

45.

Fitzgerald RS (2014) Carotid body: a new target for rescuing neural control of cardiorespiratory balance in disease. Front Physiol 5:304. https://doi.org/10.3389/fphys.2014.00304 CrossRefPubMedPubMedCentral

46.

Winter B (1973) Carotid body resection. Controversy--confusion--conflict. Ann Thorac Surg 16(6):648–659. https://doi.org/10.1016/S0003-4975(10)65048-5 CrossRefPubMed

47.

Niewinski P, Janczak D, Rucinski A et al (2017) Carotid body resection for sympathetic modulation in systolic heart failure: results from first-in-man study. Eur J Heart Fail 19(3):391–400. https://doi.org/10.1002/ejhf.641 CrossRefPubMed

48.

Niewinski P, Engelman ZJ, Fudim M, Tubek S, Paleczny B, Jankowska EA, Banasiak W, Sobotka PA, Ponikowski P (2013) Clinical predictors and hemodynamic consequences of elevated peripheral chemosensitivity in optimally treated men with chronic systolic heart failure. J Card Fail 19(6):408–415. https://doi.org/10.1016/j.cardfail.2013.03.013 CrossRefPubMed

49.

Andrade DC, Lucero C, Toledo C, Madrid C, Marcus NJ, Schultz HD, del Rio R (2015) Relevance of the carotid body chemoreflex in the progression of heart failure. Biomed Res Int 2015:467597. https://doi.org/10.1155/2015/467597 CrossRefPubMedPubMedCentral

50.

Del Rio R, Marcus NJ, Schultz HD (2013) Carotid chemoreceptor ablation improves survival in heart failure: rescuing autonomic control of cardiorespiratory function. J Am Coll Cardiol 62(25):2422–2430. https://doi.org/10.1016/j.jacc.2013.07.079 CrossRefPubMed

51.

Niewinski P, Janczak D, Rucinski A et al (2014) Dissociation between blood pressure and heart rate response to hypoxia after bilateral carotid body removal in men with systolic heart failure. Exp Physiol 99(3):552–561. https://doi.org/10.1113/expphysiol.2013.075580 CrossRefPubMed

Titel: Devices and interventions for the prevention of adverse outcomes of tachycardia on heart failure
verfasst von: Jasneet Devgun
Yash B. Jobanputra
Michael Arustamyan
Robert Chait
Waqas Ghumman
Publikationsdatum: 12.02.2018
Verlag: Springer US
Erschienen in: Heart Failure Reviews / Ausgabe 4/2018
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-018-9680-5

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Devices and interventions for the prevention of adverse outcomes of tachycardia on heart failure

Abstract

Neu im Fachgebiet Kardiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Infectious myocarditis: the role of the cardiac vasculature

The effects of heart rate control in chronic heart failure with reduced ejection fraction

Anticoagulation in atrial fibrillation with heart failure

Expanded algorithm for managing patients with acute decompensated heart failure

Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis

Heart rate during exercise: mechanisms, behavior, and therapeutic and prognostic implications in heart failure patients with reduced ejection fraction

Neu im Fachgebiet Kardiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Update Kardiologie